Download PDF
Klin Padiatr 2013; 225(S 01): S50-S56
DOI: 10.1055/s-0033-1337964
Zum 80. Geburtstag von Prof. Riehm
© Georg Thieme Verlag KG Stuttgart · New York

Prediction of Outcome by Early Response in Childhood Acute Lymphoblastic Leukemia

Das frühe Ansprechen auf die Therapie als prognostischer Faktor bei der akuten lymphoblastischen Leukämie im Kindesalter
A. Möricke
1   Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Germany
,
M. Lauten
2   Pediatric Hematology and Oncology, University Hospital Schleswig-­Holstein, Campus Lübeck, Germany
,
R. Beier
3   Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
,
E. Odenwald
3   Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
,
M. Stanulla
1   Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Germany
,
M. Zimmermann
3   Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
,
A. Attarbaschi
4   St. Anna Children’s Hospital, Vienna, Austria
,
F. Niggli
6   Kinderspital, University Hospital Zürich, Switzerland
,
M. Schrappe
1   Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
22 May 2013 (online)

Also available at
    Permissions and Reprints

Abstract

Background:

In the ALL-BFM studies for treatment of acute lymphoblastic leukemia, reduction of leukemic blasts in peripheral blood after a one-week prednisone pre-phase – the so-called prednisone response – has been used for risk stratification since the 1980s and has been one of the most relevant factors for identification of high-risk patients. In the trial ALL-BFM 95, early cytomorphological marrow response on day 15 of induction therapy was prospectively evaluated and its prognostic value was analyzed in comparison to the prednisone response and other established prognostic factors.

Results:

Compared to prednisone response, day 15 marrow response was superior in outcome prediction – yet with differential effect depending on blast lineage. Outcome was poor in T cell leukemia patients with prednisone poor-response independent of day 15 marrow response, whereas among patients with prednisone good-response different risk groups could be identified by day 15 marrow response. In contrast, prednisone response lost prognostic significance in precursor B cell leukemia when stratified by day 15 marrow response.

Conclusions:

Selective addition of day 15 marrow response to conventional stratification criteria applied on ALL-BFM 95 may significantly improve risk-adapted treatment delivery. Even though cutting-edge trial risk stratification is meanwhile dominated by minimal residual disease evaluation, an improved conventional risk assessment, as presented here, could be of great importance to countries lacking the technical and/or financial resources associated with the application of minimal residual disease analysis.

Zusammenfassung

Hintergrund:

Die Blastenreduktion im peri­pheren Blut nach einer einwöchigen Prednison-Vorphase – der sogenannte Prednison-Response – wird in den ALL-BFM-Studien zur Behandlung von Kindern mit akuter lymphoblastischer Leukämie seit den 1980er Jahren für die Risikostratifizierung herangezogen und stellt einen der wichtigsten Faktoren für die Identifizierung von Hochrisikopatienten dar. In der Studie ALL-BFM 95 wurde zusätzlich das frühe zytomorphologische Ansprechen auf die Therapie am Tag 15 der Induktionstherapie im Knochenmark pro­spektiv untersucht und dessen prognostischer Wert im Vergleich zum Prednison-Response und anderen etablierten Prognosefaktoren analysiert.

Ergebnisse:

Das zytomorphologische Ansprechen im Knochenmark am Tag 15 war als prognostischer Faktor dem Prednison-Response insgesamt überlegen, jedoch mit unterschiedlichem Effekt in Abhängigkeit vom Immunphänotyp der Blasten. Während bei Patienten mit B-Vorläuferzell-Leukämie der Prednison-Reponse in Kombination mit dem Ansprechen am Tag 15 seine prognostische Wertigkeit komplett verlor, war bei Patienten mit T-Zell-Leukämie ein ­schlechter Prednison-Response auch bei gutem Ansprechen am Tag 15 prognostisch ungünstig.

Schlussfolgerung:

Die Verwendung des zytomorphologischen Therapieansprechens am Tag 15 in der Induktionstherapie für die Risikostra­tifizierung kann im Vergleich zur konventionellen Stratifizierung der Studie ALL-BFM 95 eine bessere Risikoadaptierung der Therapie ermöglichen. Auch wenn mittlerweile in vielen aktuellen Therapiestudien die zytomorphologische Evaluation des Therapieansprechens weitgehend durch Methoden zur Erfassung der minimalen Resterkrankung abgelöst wurde, kann insbesondere in Ländern, in denen keine ausreichenden Mittel für Analysen der minimalen Resterkrankung ­verfügbar sind, eine verbesserte konventionelle Risikoeinschätzung entscheidend zur Qualität der Therapie beitragen.

Key words

childhood acute lympho­blastic leukemia - early treatment response - clinical trial

Schlüsselwörter

akute lymphomblastische Leukämie in der Kindheit - frühes Therapieansprechen - klinische Studie
 

  • References

  • 1 Arico M, Basso G, Mandelli F et al. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Cancer 1995; 75: 1684-1693
    PubMedGoogle Scholar
  • 2 Bowman WP, Larsen EL, Devidas M et al. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children’s Oncology Group trial P9906. Pediatr Blood Cancer 2011; 57: 569-577
    CrossrefPubMedGoogle Scholar
  • 3 Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet 1995; 345: 143-148
    CrossrefPubMedGoogle Scholar
  • 4 Conter V, Bartram CR, Valsecchi MG et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-3214
    CrossrefPubMedGoogle Scholar
  • 5 Dordelmann M, Reiter A, Borkhardt A et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209-1217
    PubMedGoogle Scholar
  • 6 Felice MS, Zubizarreta PA, Alfaro EM et al. Childhood acute lymphoblastic leukemia: prognostic value of initial peripheral blast count in good responders to prednisone. J Pediatr Hematol Oncol 2001; 23: 411-415
    CrossrefPubMedGoogle Scholar
  • 7 Fronkova E, Mejstrikova E, Avigad S et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing?. Leukemia 2008; 22: 989-997
    PubMedGoogle Scholar
  • 8 Gajjar A, Ribeiro R, Hancock ML et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995; 86: 1292-1295
    PubMedGoogle Scholar
  • 9 Gaynon PS. Prognostic factors in acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2000; 22: 403-404
    CrossrefPubMedGoogle Scholar
  • 10 Gaynon PS, Angiolillo AL, Carroll WL et al. Long-term results of the children’s cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: a Children’s Oncology Group Report. Leukemia 2010; 24: 285-297
    PubMedGoogle Scholar
  • 11 Gaynon PS, Bleyer WA, Steinherz PG et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990; 18: 273-279
    CrossrefPubMedGoogle Scholar
  • 12 Gaynon PS, Desai AA, Bostrom BC et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997; 80: 1717-1726
    CrossrefPubMedGoogle Scholar
  • 13 Gaynon PS, Trigg ME, Heerema NA et al. Children’s Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000; 14: 2223-2233
    CrossrefPubMedGoogle Scholar
  • 14 Haw R, Sawka CA, Franssen E et al. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin’s lymphoma: a literature review. J Clin Oncol 1994; 12: 1074-1084
    PubMedGoogle Scholar
  • 15 Keating MJ, Smith TL, Gehan EA et al. Factors related to length of complete remission in adult acute leukemia. Cancer 1980; 45: 2017-2029
    CrossrefPubMedGoogle Scholar
  • 16 Lange BJ, Bostrom BC, Cherlow JM et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood 2002; 99: 825-833
    CrossrefPubMedGoogle Scholar
  • 17 Lauten M, Moricke A, Beier R et al. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica 2012; 97: 1048-1056
    CrossrefPubMedGoogle Scholar
  • 18 Lauten M, Stanulla M, Zimmermann M et al. Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter. Klin Padiatr 2001; 213: 169-174
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Matloub Y, Bostrom BC, Hunger SP et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood 2011; 118: 243-251
    CrossrefPubMedGoogle Scholar
  • 20 Matloub Y, Lindemulder S, Gaynon PS et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children’s Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children’s Oncology Group. Blood 2006; 108: 1165-1173
    CrossrefPubMedGoogle Scholar
  • 21 Miller DR, Leikin S, Albo V et al. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141. A report from childrens cancer study group. Cancer 1983; 51: 1041-1049
    PubMedGoogle Scholar
  • 22 Miller DR, Leikin S, Albo V et al. Use of prognostic factors in improving the design and efficiency of clinical trials in childhood leukemia: Children’s Cancer Study Group Report. Cancer Treat Rep 1980; 64: 381-392
    PubMedGoogle Scholar
  • 23 Möricke A, Reiter A, Zimmermann M et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111: 4477-4489
    CrossrefPubMedGoogle Scholar
  • 24 Möricke A, Zimmermann M, Reiter A et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010; 24: 265-284
    PubMedGoogle Scholar
  • 25 Nachman J, Sather HN, Gaynon PS et al. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children’s Cancer Group. J Clin Oncol 1997; 15: 2222-2230
    PubMedGoogle Scholar
  • 26 Oudot C, Auclerc MF, Levy V et al. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol 2008; 26: 1496-1503
    CrossrefPubMedGoogle Scholar
  • 27 Reiter A, Schrappe M, Ludwig WD et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-3133
    PubMedGoogle Scholar
  • 28 Riehm H, Reiter A, Schrappe M et al. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr 1987; 199: 151-160
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Sandlund JT, Harrison PL, Rivera G et al. Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood 2002; 100: 43-47
    CrossrefPubMedGoogle Scholar
  • 30 Schrappe M, Reiter A, Riehm H. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 2403-2406
    PubMedGoogle Scholar
  • 31 Schrappe M, Valsecchi MG, Bartram CR et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011; 118: 2077-2084
    CrossrefPubMedGoogle Scholar
  • 32 Schultz KR, Pullen DJ, Sather HN et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood 2007; 109: 926-935
    PubMedGoogle Scholar
  • 33 Seibel NL, Steinherz PG, Sather HN et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood 2008; 111: 2548-2555
    CrossrefPubMedGoogle Scholar
  • 34 Smith M, Arthur D, Camitta B et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18-24
    PubMedGoogle Scholar
  • 35 Smith M, Bleyer A, Crist W et al. Uniform criteria for childhood acute lymphoblastic leukemia risk classification. J Clin Oncol 1996; 14: 680-681
    PubMedGoogle Scholar
  • 36 Steinherz PG, Gaynon PS, Breneman JC et al. Cytoreduction and prognosis in acute lymphoblastic leukemia – the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol 1996; 14: 389-398
    PubMedGoogle Scholar
  • 37 Thyss A, Suciu S, Bertrand Y et al. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukaemia. The European Organization for Research and Treatment of Cancer Children’s Leukemia Cooperative Group. J Clin Oncol 1997; 15: 1824-1830
    PubMedGoogle Scholar
  • 38 Vora A, Mitchell CD, Lennard L et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 2006; 368: 1339-1348
    CrossrefPubMedGoogle Scholar